drugset / Trial / NCT01046955
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
RandomizedParallel-groupOpen-label
Summary
The purpose of this study is to observe in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with the investigators standard treatment protocol of Zenapax® and maintenance immunosuppression.
Timeline
- Start
- 2005-11
- Primary completion
- 2007-04
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alemtuzumab | Monoclonal antibody | 0.3 mg/kg | — |
| Comparator | Daclizumab | Monoclonal antibody | 1 mg/kg | — |
| Comparator | Thymoglobulin | Protein / enzyme biologic | 1 mg/kg | — |